Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Share-based Compensation (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Share-based Compensation for 16 consecutive years, with $600000.0 as the latest value for Q3 2025.

  • Quarterly Share-based Compensation fell 45.45% to $600000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Sep 2025, down 27.27% year-over-year, with the annual reading at $4.1 million for FY2024, 50.31% up from the prior year.
  • Share-based Compensation for Q3 2025 was $600000.0 at Xtant Medical Holdings, down from $800000.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $1.2 million in Q2 2024, with the low at $439000.0 in Q2 2023.
  • Average Share-based Compensation over 5 years is $717842.1, with a median of $641000.0 recorded in 2022.
  • The sharpest move saw Share-based Compensation skyrocketed 173.35% in 2024, then crashed 45.45% in 2025.
  • Over 5 years, Share-based Compensation stood at $708000.0 in 2021, then fell by 9.75% to $639000.0 in 2022, then surged by 46.79% to $938000.0 in 2023, then dropped by 12.9% to $817000.0 in 2024, then decreased by 26.56% to $600000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $600000.0, $800000.0, and $800000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.